Drug Profile

Research programme: gene therapies - Astellas Gene Therapies

Alternative Names: AAV-CASQ2 gene therapy - Audentes; AT 307

Latest Information Update: 08 Apr 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Audentes Therapeutics
Developer Astellas Gene Therapies
Class Cardiovascular therapies; Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Discontinued Ventricular tachycardia

Most Recent Events

01 Apr 2021 Audentes Therapeutics is now called Astellas Gene Therapies
15 Jan 2020 Audentes Therapeutics has been acquired by Astellas Pharma
24 May 2019 Discontinued - Preclinical for Ventricular tachycardia in USA (Parenteral) (Audentes Therapeutics pipeline, May 2019)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com